Investigating Innate Immune Cell Dysregulation to Improve Immunotherapies
The Mundy-Bosse Lab at the OSUCCC – James, led by tumor immunology expert and principal investigator Bethany Mundy-Bosse, PhD, is dedicated to uncovering how the innate immune system develops, then creating new immunotherapy intervention aimed at restoring patients’ normal innate immune surveillance to fight cancer.
The specialists in the Mundy-Bosse Lab recognize how immunotherapy revolutionizes cancer treatment, and they aim to further its impact by defining the mechanisms that lead to innate immune cell defects in patients with hematological malignancies. Understanding the basic building blocks of how the immune system develops will help improve the design of novel immune-based therapeutics to improve overall survival for patients with cancer.
Mission
At the OSUCCC – James, the Mundy-Bosse Lab’s mission is to improve immune-based therapeutics by understanding how the innate immune system is dysregulated in patients with hematological malignancies.
Immunotherapy is changing the future of cancer treatment, but the role of the immune system in developing cancer and in preventing relapse is still largely unknown. The Mundy-Bosse Lab focuses on detecting defects that might occur during the development of immune cell populations that are responsible for tumor immune-surveillance and anti-viral immunity, including natural killer cells and innate lymphoid cells.
Further, the team is currently exploring opportunities for therapeutic intervention aimed at restoring patients’ normal innate immunity to improve outcomes and decrease the chance of relapse.